Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-10-22 | Odysseas D. Kostas, M.D. has served as a member of our Board of Directors since February 2020. ... Dr. Kostas is a member of the Nominating and Corporate Governance Committee. ... No compensation details were provided for Dr. Kostas in the filing. |
| 2021-02-26 | Dr. Kostas, who recused themselves from the Board’s approval of the Private Placement. Dr. Kostas is affiliated with Innoviva and is expected to continue as a member of the Board following the closing of the Private Placement. |
| 2021-04-21 | Odysseas D. Kostas, M.D. has served as a member of our Board of Directors since February 2020. ... Mr. Kostas was selected as a director because of his extensive leadership experience with biotechnology companies and his in-depth knowledge of our business, strategy and management team, as well as his experience serving as a public company director. |
| 2022-03-09 | As of the date of this Agreement, Dr. Odysseas Kostas MD and Jules Haimovitz are the Investor Designees. |
| 2022-10-17 | Odysseas D. Kostas, M.D. has served as a member of our board of directors since February 2020. He also currently serves as a director of Innoviva, Inc. He is a Partner and Senior Managing Director at Sarissa Capital Management LP. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. Prior to joining Sarissa Capital, Dr. Kostas served as a Director at Evercore ISI (formerly ISI), covering the biotechnology and pharmaceutical industries. Previously, he practiced internal medicine as part of the Yale New Haven Health System and was engaged as a consultant to various biotechnology companies. Dr. Kostas also previously served on the board of directors of Enzon Pharmaceuticals. Dr. Kostas has a B.S from Massachusetts Institute of Technology (MIT) and a M.D. from University of Texas Southwestern Medical School. Dr. Kostas has demonstrated leadership in his field, and his knowledge of and experience in our industry contributed to our conclusion that he should serve as a director. |
| 2023-08-03 | Odysseas D. Kostas, M.D. has served as a member of our board of directors since February 2020. He also currently serves as a director of Innoviva, Inc. and director/Chairman of Amarin Corporation. He is a Partner and Senior Managing Director at Sarissa Capital Management LP. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. |
| 2024-04-29 | Odysseas D. Kostas, M.D. has served as a member of our board of directors since February 2020. He also currently serves as a director of Innoviva, Inc. and director/Chairman of Amarin Corporation. He is a Partner and Senior Managing Director at Sarissa Capital Management LP. |
| Filing Date | Source Excerpt |
|---|---|
| 2018-03-23 | Odysseas D. Kostas, M.D. has served as a member of our Board of Directors since December 2017 and is currently a member of the Compensation Committee of the Board of Directors (the "Compensation Committee") and the Nominating/Corporate Governance Committee of the Board of Directors (the "Nominating/Corporate Governance Committee"). |
| 2019-03-13 | Odysseas D. Kostas, M.D. has served as a member of our Board of Directors since December 2017 and is currently a member of the Audit Committee and the Nominating/Corporate Governance Committee. He is a Partner and Senior Analyst at Sarissa Capital Management LP. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. Prior to joining Sarissa Capital, Dr. Kostas served as a Director at Evercore ISI (formerly ISI), covering the biotechnology and pharmaceutical industries. Previously, he practiced internal medicine as part of the Yale New Haven Health System and was engaged as a consultant to various biotechnology companies. Dr. Kostas currently serves on the board of directors of Enzon Pharmaceuticals. Dr. Kostas has a B.S from Massachusetts Institute of Technology (MIT) and a M.D. from University of Texas Southwestern Medical School. Dr. Kostas has demonstrated leadership in his field, his knowledge of our industry and experience in our industry contributed to our conclusion that he should serve as a director. |
| 2020-03-11 | Odysseas D. Kostas, M.D. has served as a member of our Board of Directors since December 2017 and as Chairman of the Board of Directors since April 2018. He is currently a member of the Audit Committee and the Nominating Committee. |
| 2021-04-02 | Odysseas D. Kostas, M.D. has served as a member of our Board of Directors since December 2017 and was Chairman of the Board of Directors from April 2018 until December 2020. |
| 2022-03-25 | Odysseas D. Kostas, M.D. has served as a member of our Board of Directors since December 2017. He is a Partner and Senior Managing Director at Sarissa Capital Management LP, which he joined in 2016. Sarissa Capital Management LP focuses on improving the strategies of companies to enhance shareholder value. From 2011-2015, Dr. Kostas was at Evercore ISI covering the biotechnology and pharmaceutical industries, most recently as a Director. Prior to joining Evercore, Dr. Kostas was a Consultant and Senior Associate Analyst at Sanford C. Bernstein and Co., Inc. Previously, he practiced internal medicine as part of the Yale New Haven Health system and was engaged as a consultant to various biotechnology companies. Dr. Kostas currently serves on the board of directors of Armata Pharmaceuticals, Inc. and previously served on the board of directors of Enzon Pharmaceuticals, Inc. Dr. Kostas holds a BS from Massachusetts Institute of Technology (MIT) and a M.D. from University of Texas Southwestern Medical School. Dr. Kostas has demonstrated leadership in his field, his knowledge of our industry and experience in our industry contributed to our conclusion that he should serve as a director. |
| 2023-04-28 | Odysseas D. Kostas, M.D. has served as a member of our Board of Directors since December 2017. ... 2022 Director Compensation Table ... Odysseas D. Kostas, M.D. 50,000 Fees Earned or Paid in Cash, 224,990 Stock Awards, 132,500 Option Awards, Total 407,490. |
| 2024-04-29 | Odysseas D. Kostas, M.D. has served as a member of our Board of Directors since December 2017. ... 2023 Director Compensation Table ... Odysseas D. Kostas, M.D. 50,000 224,992 56,188 331,180 |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22